Stockreport

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Inc.  (NSPR) 
NASDAQ:AMEX Investor Relations: inspiremd.com/en/investors/investor-relations
PDF MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, t [Read more]